Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The Effect Of Eplerenone Versus Placebo On Cardiovascular Mortality And Heart Failure Hospitalization In Subjects With NYHA Class II Chronic Systolic Heart Failure

Next Previous
X
Search
Trial Profile

The Effect Of Eplerenone Versus Placebo On Cardiovascular Mortality And Heart Failure Hospitalization In Subjects With NYHA Class II Chronic Systolic Heart Failure

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 26 Dec 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Eplerenone (Primary)
  • Indications Chronic heart failure
  • Focus Registrational; Therapeutic Use
  • Acronyms EMPHASIS-HF
  • Sponsors Pfizer

    • Most Recent Events

    • 13 Nov 2023 Results developing and validating a mathematical model of HFrEF and GDMT treatment based on EMPHASIS-HF, PARADIGM-HF and DAPA-HF, presented at the American Heart Association Scientific Sessions 2023
    • 01 Aug 2023 Results assessing the safety and efficacy of eplerenone according to duration of HFrEF published in the Journal of the American College of Cardiology
    • 15 Feb 2019 Results published in the European Journal of Heart Failure

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top